NCT00286442 - Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus | Biotech Hunter

Enrollment

527

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions

Diabetes Mellitus

Interventions

DRUG

Alogliptin and metformin

Alogliptin 12.5 mg, tablets, orally, once daily and metformin for up to 26 weeks.

DRUG

Alogliptin and metformin

Alogliptin 25 mg, tablets, orally, once daily and metformin for up to 26 weeks.

DRUG

Metformin

Alogliptin placebo-matching tablets, orally, once daily and metformin for up to 26 weeks.

Trial Locations (56)

Unknown

Phoenix

Anaheim

Artesia

Fresno

Los Angeles

Mission Viejo

Northridge

Orange

San Diego

Walnut Creek

Denver

Washington D.C.

Cocoa Beach

Longwood

Ocala

Ocoee

Saint Cloud

Honolulu

Avon

Elkhart

Evansville

St Louis

Omaha

Berlin

Burlington

Hickory

Morehead City

Pinehurst

Winston-Salem

Cincinnati

Medford

Lansdale

Charleston

Columbia

Simpsonville

Corpus Christi

Dallas

San Antonio

Texarkana

Burlington

Multiple Cities